Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.
Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.
Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.
Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.
Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.
With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.
Arcus Biosciences, Inc. (NYSE:RCUS) announces the granting of stock options and restricted stock units to nine new employees. A total of 22,100 options were provided at an exercise price of $27.35, reflecting the closing price on August 8, 2022. Additionally, 11,050 restricted stock units were awarded. These grants are in accordance with the Company’s 2020 Inducement Plan, approved in January 2020, under NYSE Rule 303A.08. Arcus is focused on developing innovative cancer therapies and has advanced six investigational medicines into clinical studies.
Arcus Biosciences (NYSE:RCUS) appointed Dr. Dimitry S.A. Nuyten as Chief Medical Officer effective August 1, 2022. Dr. Nuyten will lead the clinical development organization, comprising nearly 200 employees and six clinical-stage programs, including four ongoing Phase 3 trials for domvanalimab in combination therapies targeting various cancers. His extensive background includes leadership roles at Nektar Therapeutics and Pfizer. Arcus aims to expedite the development of innovative cancer treatments through collaborations, notably with Gilead, which invested $200 million into the company in 2020.
Arcus Biosciences (NYSE: RCUS) reported its second-quarter financial results, revealing collaboration and license revenues of $26.8 million, up from $9.5 million year-over-year. The company's cash position stands strong at $1.3 billion, sufficient to fund operations into 2026. Notable updates include ongoing Phase 3 trials for domvanalimab-based therapies in NSCLC and gastrointestinal cancers. The interim analysis of the ARC-8 trial for quemliclustat indicates no significant safety issues, but final data on progression-free and overall survival are awaited in 2023.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, will engage in a virtual fireside chat at the 13th Annual Wedbush PacGrow Healthcare Conference. The event is scheduled for August 10, 2022, at 12:00 p.m. ET. Interested parties can access a live webcast via the Arcus Biosciences website, with a replay available post-event. Founded in 2015, Arcus is advancing six investigational medicines aimed at targeting cancer pathways.
Arcus Biosciences, Inc. (NYSE:RCUS) announced that its Compensation Committee granted options to six employees for a total of 10,200 shares at an exercise price of $26.19, the closing price on July 25, 2022. Additionally, they received restricted stock units for 5,100 shares. These equity awards were issued under the company's 2020 Inducement Plan, approved in January 2020, compliant with NYSE Listed Company Manual Rule 303A.08. Arcus is focused on developing innovative cancer therapies, advancing six investigational medicines in clinical studies.
Arcus Biosciences, Inc. (NYSE:RCUS) has granted options to purchase 34,500 shares and restricted stock units totaling 17,250 shares to 14 new employees. The options have an exercise price of $28.78, based on the closing price on July 8, 2022. This grant is under the Company's 2020 Inducement Plan, approved by the Board in January 2020. Arcus is focused on developing innovative cancer therapies and has advanced six investigational medicines to clinical studies, targeting various biological pathways.
Arcus Biosciences (NYSE:RCUS) announced the granting of equity awards to ten new employees. The Compensation Committee approved options to purchase 22,850 shares at $24.98 per share, along with restricted stock units for 11,425 shares. This initiative is part of the Company’s 2020 Inducement Plan, which aims to attract skilled professionals in the oncology-focused biopharmaceutical sector. These awards signify the company's commitment to incentivizing talent as it continues to develop innovative cancer therapies.
Arcus Biosciences, Inc. (NYSE:RCUS) announced that its Compensation Committee granted options for 35,050 shares and restricted stock units for 17,525 shares to 16 new employees. The exercise price is set at $23.62, reflecting the closing stock price on June 8, 2022. These grants were made under the company's 2020 Inducement Plan, approved in January 2020. The company focuses on developing innovative cancer therapies and has accelerated six investigational drugs into clinical trials since its founding in 2015.
Arcus Biosciences (NYSE:RCUS) will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference on Thursday, June 16, 2022, at 9:20 a.m. PT. This event will be held at the Terranea Resort in Rancho Palos Verdes, California. A live webcast can be accessed via the Investors & Media section of the Arcus website, with a replay available post-event. Arcus is focused on developing innovative treatments for cancer, having advanced six investigational medicines into clinical studies since its founding in 2015.
Arcus Biosciences, Inc. (NYSE:RCUS) has granted stock options to fifteen new employees, allowing them to purchase 49,650 shares at an exercise price of $19.08, the closing price on May 23, 2022. Additionally, restricted stock units were awarded for 21,725 shares. These equity awards are in line with the 2020 Inducement Plan approved by the Board of Directors in January 2020. Arcus is dedicated to developing innovative cancer therapies, emphasizing the advancement of first- or best-in-class medicines targeting various cancer-related biology and pathways.
FAQ
What is the current stock price of Arcus Biosciences (RCUS)?
What is the market cap of Arcus Biosciences (RCUS)?
What does Arcus Biosciences, Inc. do?
Where is Arcus Biosciences located?
When was Arcus Biosciences founded?
What is the core focus of Arcus Biosciences' research?
What are some of Arcus Biosciences' main products?
What types of cancer does Arcus Biosciences target?
Does Arcus Biosciences outsource its research and development?
With whom does Arcus Biosciences have significant partnerships?
What makes Arcus Biosciences unique?
What is the mission of Arcus Biosciences?
